Potential clinical value of circulating tumor cells in predicting progression for atypical teratoid rhabdoid tumor in young children - Top-Institutions - MDSpire

Potential clinical value of circulating tumor cells in predicting progression for atypical teratoid rhabdoid tumor in young children

  • By

  • Wei Zhang

  • Ke Cao

  • Xiaoling Zhang

  • Nianhua Cao

  • Lidan Xiao

  • Zongbin Liu

  • Xiuli Yuan

  • Jingsheng Wang

  • October 28, 2025

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    St. Jude Children's Research Hospital
    St. Jude Children's Research Hospital

    Memphis, TN

    Key Differentiators

    • Pediatric Neuro-Oncology
    • Pediatric Hematology-Oncology
    • Translational Cancer Research

  • #2

    Dana-Farber/Boston Children's Cancer and Blood Disorders Center
    Dana-Farber/Boston Children's Cancer and Blood Disorders Center

    Boston, MA

    Key Differentiators

    • Pediatric Neuro-Oncology
    • Cancer Biology
    • Molecular Diagnostics

  • #3

    Children's Hospital of Philadelphia (CHOP)
    Children's Hospital of Philadelphia (CHOP)

    Philadelphia, PA

    Key Differentiators

    • Pediatric Neuro-Oncology
    • Neurosurgery
    • Cancer Genomics

  • #4

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Pediatric Neuro-Oncology
    • Cancer Immunotherapy
    • Molecular Pathology

Original Source(s)

Potential clinical value of circulating tumor cells in predicting progression for atypical teratoid rhabdoid tumor in young children

  • by Wei Zhang, Ke Cao, Xiaoling Zhang, Nianhua Cao, Lidan Xiao, Zongbin Liu, Xiuli Yuan, Jingsheng Wang

  • October 28, 2025

Related Content

Recurrent IDH-mutant astrocytoma WHO grade 4 diagnosed during pregnancy: case report with literature review

Percutaneous nephrostomy as a marker of clinical vulnerability in non-metastatic muscle-invasive bladder cancer: prognostic and infectious implications

Characteristics and risk factors of immune-related adverse events in patients receiving immune checkpoint inhibitor combination therapy